Form D · Biotechnology
Meissa Vaccines Inc
South San Francisco, CA · CIK 0001719789
Offering snapshot reported Oct 2, 2019 · SEC filing
- Reported sold
- $13.9M Offering amount: $33.9M
- Investors reported
- 37 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 17, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 2, 2019 | Initial | $13,916,583 | No comparison | 37 | SEC filing |
| Oct 16, 2017 | Initial | $1,241,084 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-350196
Series A Preferred Stock and the Common Stock issuable upon conversion thereof.
Source: Form D, filed Oct 2, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Isaac Cheng | Director |
| William Daly | Director |
| Kenneth Kelley | Director |
| Martin Moore | Director, Executive |
| Stephanie O?Brien | Director |
| Roderick Tang | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
329 Oyster Point Boulevard 3 Rd Floor
South San Francisco, CA, 94080
South San Francisco, CA, 94080